Research programme: Alzheimer's disease therapeutics - Neuro-Hitech

Drug Profile

Research programme: Alzheimer's disease therapeutics - Neuro-Hitech

Alternative Names: 2,3,4-Trihydroxybenzophenone; 4-Amino 1,1'-azobenzene-3,4'-disulfonic acid sodium salt

Latest Information Update: 25 Feb 2014

Price : $50

At a glance

  • Originator Neuro-Hitech
  • Class
  • Mechanism of Action Amyloid beta-protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 25 Feb 2014 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
  • 02 Nov 2006 Preclinical trials in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top